Loading the company…
Loading the company…
㈜엔딕
English name as filed with DART, Korea’s corporate disclosure system · Correct the English name ›
Last updated 2026-11-02 · Korean page ›
Verification level — how far we have checked
L0 · Public records — NPS workforce · filed financials · patents — public data
A company based in Gyeonggi, founded in 2014. Industry: R&D & Professional Services. Revenue for 2025 was ₩15.5bn. It has 71 employees enrolled in the National Pension Service (as of Aug 2026). It is externally audited; the latest audit opinion is “Unqualified”.
Loading…
Latest filing 2022-06-15 · latest registration 2024-02-28 · newest first
본 발명은 5-히드록시-1-메틸이미다졸리딘-2,4-디온 화합물을 유효성분으로 포함하는 동물용 약학적 조성물에 관한 것으로, 구체적으로 본 발명은 5-히드록시-1-메틸이미다졸리딘-2,4-디온 화합물 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 동물용 신장질환의 예방 또는 치료용 조성물, 상기 화합물을 이용한 동물의 신장질환 치료방법 및 상기 화합물을 유효성분으로 포함하는 동물용 신장질환의 예방 또는 개선용 기능성 사료에 관한 것이다. 본 발명에 따른 5-히드록시-1-메틸이미다졸리딘-2,4-디온 화합물은 신장질환이 발병된 개 또는 고양이와 같은 반려동물에게 투여할 경우, 신장질환의 증상을 효과적으로 개선 및 치료할 수 있는 특징이 있다. 그러므로 본 발명은 반려동물의 높은 사망률의 원인인 신장질환을 효과적으로 치료할 수 있는 새로운 동물용 신장질환 치료제 및 신장질환의 치료방법을 제공하는 효과가 있다.
KIPO KIPRIS · checked 2026-10-15 · newest filings first · right: registration date (filing date if not yet registered) · 1 of 1 · titles and abstracts are in Korean as filed · click a row for details ▾
For now we hold public records only (National Pension Service · DART filings · patents · registers · press). When the company files material in our IR Room, it moves to L1. We do not score or rate companies — we only state how far we have checked.
| KRW bn | 2024 | 2025 |
|---|---|---|
| Revenue | 12.4 | 15.5 |
| Gross profit (loss) | 12.4 | 15.5 |
| Selling, general and administrative expenses | 12.1 | 15.1 |
| Operating income (loss) | 0.3 | 0.4 |
| Non-operating income | 1.4 | 0.6 |
| Other gains | 0.1 | 0.0 |
| Finance income | 0.2 | 0.2 |
| Other | 1.2 | 0.3 |
| Non-operating expenses | 1.5 | 0.8 |
| Other losses | 0.0 | 0.0 |
| Finance costs | 0.3 | 0.2 |
| Other | 1.2 | 0.6 |
| Profit (loss) before tax | 0.2 | 0.1 |
| Income tax expense | 0.0 | 0.0 |
| Net income (loss) | 0.2 | 0.1 |
Revenue ₩15.5bn, up 25.1% YoY.
Operating margin 2.6% (prior 2.3%).
Net income ₩0.1bn.
Need more than is shown here? Ask for more information — full review report · valuation · executive teaser · IM · competitor analysis · due diligence. Tell us what you need and we will reply by email with scope, cost and timing.
Is this your company?
If anything here is wrong, tell us — we check it against the original and correct it. You do not need to join. If you would like your financials verified and this page completed, that is a separate process.